Zeman Marilyn, Campbell Patricia, Bain Vincent G
Division of Gastroenterology, University of Alberta, Edmonton.
Can J Gastroenterol. 2006 Jun;20(6):427-31. doi: 10.1155/2006/301232.
Postrenal transplant hepatitis C is increasing in frequency due to the high prevalence of hepatitis C among patients with renal failure. Despite this, there is still no standard hepatitis C treatment available for renal transplanted recipients. Combination antiviral hepatitis C therapy, the standard of care in the nontransplant population, is generally avoided because of documented renal graft rejection secondary to interferon treatment. A case of a male patient with postrenal transplant hepatitis C, which was associated with cryoglobulinemia and glomerulonephritis of the graft, is presented. He was treated with standard interferon with ribavirin. Sustained viral clearance was achieved despite ongoing evidence of cryoglobulinemia. Renal function, which had been deteriorating before treatment, improved as evidenced by the stabilization of serum creatinine and marked improvement of proteinuria. In conclusion, in selected patients, combination antiviral therapy may still be a viable option postrenal transplant.
由于肾衰竭患者中丙型肝炎的高患病率,肾移植后丙型肝炎的发病率正在上升。尽管如此,对于肾移植受者仍没有可用的标准丙型肝炎治疗方法。丙型肝炎联合抗病毒治疗是未移植人群的标准治疗方法,但由于有文献记载干扰素治疗继发肾移植排斥反应,所以通常避免使用。本文介绍了一例男性肾移植后丙型肝炎患者,该患者伴有冷球蛋白血症和移植肾肾小球肾炎。他接受了标准干扰素联合利巴韦林治疗。尽管持续存在冷球蛋白血症的证据,但仍实现了病毒持续清除。治疗前一直在恶化的肾功能得到改善,血清肌酐稳定以及蛋白尿显著改善证明了这一点。总之,对于选定的患者,联合抗病毒治疗在肾移植后可能仍是一种可行的选择。